Sep 3 2009
Unigene Laboratories, Inc. (OTCBB: UGNE) has reported that the U.S. District Court, Southern District of New York, has confirmed the validity of Unigene’s patent on Fortical® and issued an order permanently enjoining Apotex Inc. and Apotex Corp. from further infringement of the patent. The motion of the plaintiffs, Unigene and its licensee Upsher-Smith Laboratories, for summary judgment in the case was granted while the request for summary judgment by Apotex was denied.
“This decision is a very significant development for the plaintiffs,” commented Dr. Warren P. Levy, President and CEO of Unigene. “Although this decision may not close all of the legal proceedings, we are encouraged by the court’s decision in our favor.”